FiercePharma celebrates spring

Spring is officially here. We know that because Passover has past, and Easter is just three days away. So, rebirth is definitely in the air. In observance of Good Friday, FiercePharma will not publish tomorrow. But we'll return on Monday with another batch of spring-fresh industry news. - Tracy Staton

Suggested Articles

Novartis is rolling out positive interim phase 3 data on Zolgensma in Europe, which could support the recent launch of the SMA gene therapy there.

The new cost-cutting goal comes on top of a €2.6 billion annual savings target the company already laid out in a revamp initiated in 2018.

As hearings continued on Capitol Hill, a congressional committee said Novartis, Amgen and Mallinckrodt used routine price hikes to meet sales targets.